Pharma · Obesity & Metabolic

Body composition · Obesity · Metabolic health

Are your patients losing the right kind of weight?

With GLP-1 reshaping the obesity market, lean-mass preservation is the question every sponsor is being asked. Perspectum's quantitative MRI body composition reports muscle, visceral fat, and subcutaneous fat per patient, per visit, across multi-site programmes and longitudinal time-course studies.

Strongest signal: the Nowak IJO 2026 paper showing weight-related changes in MRI-derived body composition across large-scale obesity cohorts, already in protocol design for multiple GLP-1 / obesity programmes.

Body Composition LiverMultiScan

50k+ body composition scans processed12 GLP-1 / obesity programmes

Second pillar in Marija's pharma TA roadmap.

An outline of what this page will cover when published.

Multi-organ obesity assessment

Quality of weight loss, hepatic fat, cardiac PFR, visceral and skeletal muscle compartments. Owner: Pharma Solutions (MM). Source: Brand Review v2 A.3.

Evidence stack

Multi-organ MRI evidence base across body composition, hepatic, and cardiometabolic biomarkers, drawn from the central reference library. Owner: Translational Science. Citations governed by the tiered referencing standard (Brand Review v2 8.2). Named sponsors appear only where each is on the Section 8.1 cleared list or has individual consent on file.

Named competitive position

AMRA Medical referenced as the named alternative for body-composition-only programmes; Perspectum positioned as multi-organ. Owner: Pharma BD. Comparative claims governed by Regulatory Affairs and Legal.

Sponsor logo wall (cleared list)

Eli Lilly, Boehringer Ingelheim, Roche, Takeda, Merck are the five public-mention names. The broader pipeline is held privately and is not named on public surfaces without individual sponsor consent and a cleared claims-matrix row. Source: Brand Review v2 Section 8.1.

Trial-design consultation flow

Six-step pharma intake, distinct from the generic contact drawer. Routes by TA to the BD lead for Obesity. Source: Brand Review v2 A.5. Owner: Digital Media + Pharma BD.

Proof-band coverage

Scientific, Regulatory, Commercial, Operational, Human. Minimum three of five per Section 8.3. CMS rule, not a designer preference.

Obesity & Metabolic